{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:06Z","timestamp":1788243366294,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020982","name":"Arvelle Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015660","name":"UCB Pharma Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.yebeh.2021.107897","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:51:00Z","timestamp":1616806260000},"page":"107897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-3316","authenticated-orcid":false,"given":"Manuel","family":"Toledo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-1640","authenticated-orcid":false,"given":"Christian","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Quarato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Liv","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody M.","family":"Cleveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Wagener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.107897_b0005","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1474-4422(11)70047-3","article-title":"The pharmacological treatment of epilepsy in adults","volume":"10","author":"Perucca","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.107897_b0010","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/bjp.2008.198","article-title":"Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A","volume":"154","author":"Matagne","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.yebeh.2021.107897_b0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2021.107897_b0020","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/epi.13631","article-title":"Time to onset of sustained \u226550% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment","volume":"58","author":"Klein","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107897_b0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ane.13287","article-title":"Time course of 75%-100% efficacy response of adjunctive brivaracetam","volume":"142","author":"Klein","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107897_b0030","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.84.14_supplement.P4.276","article-title":"In vitro pharmacokinetic profile of brivaracetam (BRV) reveals low risk of drug-drug interaction (DDI) and unrestricted brain permeability","volume":"84","author":"Chanteux","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107897_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106327","article-title":"A review of the drug-drug interactions of the antiepileptic drug brivaracetam","volume":"163","author":"Moseley","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.107897_b0040","unstructured":"UCB. Briviact\u00ae (brivaracetam) EU Summary of Product Characteristics 2020."},{"key":"10.1016\/j.yebeh.2021.107897_b0045","unstructured":"UCB. Briviact\u00ae (brivaracetam) US Prescribing Information 2018."},{"key":"10.1016\/j.yebeh.2021.107897_b0050","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/epi.13409","article-title":"Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy","volume":"57","author":"Klein","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107897_b0055","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107897_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106864","article-title":"Safety and tolerability of adjunctive brivaracetam in epilepsy: in-depth pooled analysis","volume":"103","author":"Brandt","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107897_b0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression Scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.yebeh.2021.107897_b0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1528-1157.1998.tb01278.x","article-title":"Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory","volume":"39","author":"Cramer","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107897_b0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.yebeh.2011.12.023","article-title":"Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures","volume":"23","author":"Borghs","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107897_b0080","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/epi.12548","article-title":"Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial","volume":"55","author":"Guerrini","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107897_b0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eplepsyres.2015.04.011","article-title":"Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel","volume":"114","author":"Montouris","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.107897_b0090","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/ane.12451","article-title":"Long-term adjunctive lacosamide treatment in patients with partial-onset seizures","volume":"133","author":"Rosenow","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107897_b0095","series-title":"Long-term retention, efficacy and tolerability of adjunctive brivaracetam by number of lifetime antiepileptic drugs in adults with focal seizures: a post hoc analysis","author":"Klein","year":"2020"},{"key":"10.1016\/j.yebeh.2021.107897_b0100","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/epi.13416","article-title":"Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures","volume":"57","author":"Toledo","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107897_b0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eplepsyres.2017.10.008","article-title":"Long-term retention rates for antiepileptic drugs: a review of long-term extension studies and comparison with brivaracetam","volume":"138","author":"Toledo","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.107897_b0110","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/ijerph16081451","article-title":"A meta-analysis of the rates of suicide ideation, attempts and deaths in people with epilepsy","volume":"16","author":"Abraham","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.yebeh.2021.107897_b0115","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/epi.16484","article-title":"Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: an up to 11-year, open-label, follow-up trial","volume":"61","author":"O'Brien","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107897_b0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.yebeh.2016.11.031","article-title":"Health-related quality of life in double-blind phase III studies of brivaracetam as adjunctive therapy of focal seizures: a pooled, post-hoc analysis","volume":"69","author":"Brandt","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107897_b0125","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107897_b0130","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy","volume":"22","author":"ILAE","year":"1981","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021001311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021001311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:35:16Z","timestamp":1761503716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021001311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":26,"alternative-id":["S1525505021001311"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107897","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107897"}}